Results 31 to 40 of about 4,586,589 (282)

Patient journey and decision processes for anti-amyloid therapy in Alzheimer's disease. [PDF]

J Neurol
Abstract Introduction We utilized the Veterans Affairs Healthcare System administrative database to study the clinical decision-making processes for anti-amyloid therapy (AAT). Methods Patients with clinical notes mentioning lecanemab were identified (March 2023–June 2024)
Mittler B, Cambi X, Biskach M, Reisman J, Wang Y, Berlowitz D, Morin P, Miller DR, Brandao-Viruet K, Clare SJ, Xia KZ, Tahami Monfared AA, Irizarry M, Zhang Q, Xia W.   +14 more
europepmc   +3 more sources

Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers? [PDF]

The amyloid cascade hypothesis for Alzheimer’s disease is still alive, although heavily challenged. Effective anti-amyloid immunotherapy would confirm the hypothesis’ claim that the protein amyloid-beta is the cause of the disease.
Alavi, Abass, Poul F. Høilund-Carlsen, Perry, George, Mona-Elisabeth Revheim, Neve, Rachael L., Revheim, Mona Elisabeth, Barrio, Jorge R., George Perry, Jorge R. Barrio, Høilund-Carlsen, Poul F., Revheim, Mona-Elisabeth, Rudolph J. Castellani, Rachael L. Neve, Abass Alavi, Castellani, Rudolph J.   +14 more
core   +1 more source

A direct interaction between mitochondrial proteins and amyloid-β peptide and its significance for the development and treatment of Alzheimer’s disease [PDF]

, 2015
This work was supported by the Ministry of Education, Youth and Sports CZ (no. LD14009, no. SV/FVZ201201, no. SVV260062), COST CM1103, MH CZ - DRO (UHHK, 00179906), The Alzheimer’s Society, The Barcopel Foundation and the MSD Scottish Life Sciences fund ...
Gunn-Moore, Frank J, Musilek, Kamil, Benek, Ondrej, Kuca, Kamil, Aitken, Laura, Hroch, Lukas, Gunn-Moore, Frank J; id_orcid, Aitken, Laura; id_orcid   +7 more
core   +1 more source

Anti‐amyloid antibody treatments for Alzheimer's disease [PDF]

, 2023
Our aim is to review the most recent evidence on novel antibody therapies for Alzheimer's disease directed against amyloid-β. This is a joint statement of the European Association of Neurology and the European Psychiatric Association.
Dom, Geert, Bassetti, Claudio, Bassetti, C., Perneczky, R., Falkai, Peter, Robert Perneczky, Geert Dom, Falkai, P., Chan, A., Perneczky, Robert, Bassetti, Claudio L. A., Andrew Chan, Chan, Andrew, Peter Falkai, Claudio Bassetti, Dom, G.   +15 more
core   +2 more sources

Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer's disease

Neurobiology of Disease, 2014
Alzheimer's disease is a complex disease characterized by overlapping phenotypes with different neurodegenerative disorders. Oligomers are considered the most toxic species in amyloid pathologies. We examined human AD brain samples using an anti-oligomer
Marcos J. Guerrero-Muñoz, Diana L. Castillo-Carranza, Shashirekha Krishnamurthy, Adriana A. Paulucci-Holthauzen, Urmi Sengupta, Cristian A. Lasagna-Reeves, Yembur Ahmad, George R. Jackson, Rakez Kayed   +8 more
doaj   +1 more source

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease [PDF]

, 2022
Background This review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer’s disease (AD).
Randall J. Bateman, Blennow, Kaj,, Paulo Fontoura, Smith, Janice, Bateman, Randall J, Boada, Mercè, Doody, Rachelle S., Doody, Rachelle S, Kaj Blennow, Bruno Vellas, Klein, Gregory, Stephen Salloway, Rachelle S. Doody, Scott Schobel, Jeffrey Cummings, Vellas, Bruno, Assunção, Sheila Seleri, Janice Smith, Salloway, Stephen, Gregory Klein, Sandra E. Black, Black, Sandra E, Sheila Seleri Assunção, Black, Sandra E., Schobel, Scott, Bateman, Randall J., Fontoura, Paulo, Mercè Boada, Blennow, Kaj, Cummings, Jeffrey, Black, Sandra, E, Doody, Rachelle, S, Bateman, Randall, J, Assunção, Sheila, Seleri   +33 more
core   +1 more source

Drugs used in the treatment of Alzheimer’s disease: a review of current clinical research and promising therapeutic targets

Сибирский научный медицинский журнал
Medications used in Alzheimer’s disease are currently aimed primarily at eliminating the symptoms of the disease, while more modern drugs based on monoclonal antibodies are still of limited use.
K. N. Sorokina, T. G. Tolstikova, V. Yu. Usov, A. A. Tulupov   +3 more
doaj   +1 more source

ANTIAMYLOIDOGENIC EFFECT OF MiR-101 IN EXPERIMENTAL ALZHEIMER’S DISEASE [PDF]

Biotechnologia Acta, 2019
The aim of the study was to determine the effect of miR-101 on the level of β-amyloid peptide and activation of the cytokine system in the brain regions of animals with an experimental model of Alzheimer’s disease.
V. Sokolik, O. Berchenko, N. Levicheva, S. Shulga   +3 more
doaj  

Microbiome−host proteostasis crosstalk—An emerging perspective on mechanisms and interventions toward healthy longevity

FEBS Letters, EarlyView.
Proteostasis and the gut microbiota play a key role in shaping host physiology. Microbiota‐derived metabolites, vitamins, and RNA modulate host proteostasis. Findings from model systems, including C. elegans, indicate microbes can either stabilize or disrupt host proteostasis.
Abhishek Anil Dubey, Maria Ermolaeva
wiley   +1 more source

Rate of β-amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials [PDF]

, 2018
INTRODUCTION: This study examined a longitudinal trajectory of β-amyloid (Aβ) accumulation at the predementia stage of Alzheimer's disease in the context of clinical trials. METHODS: Analyzed were baseline (BL) and 2 years' follow-up 18F-florbetapir
Tengfei Guo, Dukart, Juergen, Grimmer, Timo, Igor Yakushev, Guo, Tengfei, Rominger, Axel Oliver, Brendel, Matthias, Juergen Dukart, Axel Rominger, Matthias Brendel, Timo Grimmer, Yakushev, Igor, Grimmer T, Guo T, Rominger A, Yakushev I, Dukart J, Brendel M   +17 more
core   +1 more source